This application seeks to renew the Alzheimer's Disease Core Center (P30 AG028383) at the University of Kentucky (UK-ADC), a mature and experienced ADC that was originally funded in 1985. Our principal mission is to serve as the focal point for all AD-related activities at UK and the Commonwealth of Kentucky, by providing an environment and core resources that catalyze innovative research, outreach and education, and clinical programs that benefit elderly Kentuckians. Over the past 25 years, we have developed a vigorous program in the clinical, neuropathological, educational, and research aspects of AD that serves as a critical resource for the university, community, state, region and nation. UK-ADC initiatives are innovative and are shifting the current research and clinical practice paradigms. Two of the historically outstanding facets of our ADC are: 1) a strong program in clinical-neuropathological correlations and short postmortem interval autopsies, and 2) a unique normal control group of -500 subjects followed longitudinally, with all committed to brain autopsy upon death. These resources have contributed to us becoming one of the premier Centers in defining pathogenic mechanisms underlying the transitions from normal cognitive aging to AD. With the recent change in leadership of our ADC, we are poised to build on these strengths and capitalize on emerging opportunities to more effectively translate this knowledge into therapeutic strategies aimed at slowing progression or preventing development of AD. Thus, the UK-ADC will focus on two interrelated themes: Transitions and Translation. Our emphasis moving forward will be to more effectively bridge the gap between basic research and clinical studies by providing support and the necessary infrastructure to facilitate translational efforts. Efforts are focused across the spectrum of cognitive impairment (normal/ preclinical AD/ MCI/ dementia), with an overall goal of more effective translation of knowledge to intervention strategies. The UK-ADC provides an infrastructure and environment that focuses on these integrated themes and advances multidisciplinary, innovative AD research through five highly interactive and effective Cores: A: Administrative, B: Clinical (including our successful Minority Gateway Satellite), C: Biostatistics and Data Management, D: Neuropathology, and E: Education and Information Transfer Cores.
The UK-ADC has historically been at the forefront of supporting research to identify the early manifestations of disease and the pathogenic mechanisms underlying the transitions from normal aging to the development of AD. We propose to build upon this highly successful focus, as well as leverage several recent positive developments at UK that will expand our translational research capability, and thereby help to increase the rate of progress toward new therapies to delay or prevent AD.
|Perez, Sylvia E; He, Bin; Nadeem, Muhammad et al. (2015) Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease. Biol Psychiatry 77:693-703|
|Segerstrom, Suzanne C; Eisenlohr-Moul, Tory A; Evans, Daniel R et al. (2015) Repetitive thought dimensions, psychological well-being, and perceived growth in older adults: a multilevel, prospective study. Anxiety Stress Coping 28:287-302|
|Powell, David; Caban-Holt, Allison; Jicha, Gregory et al. (2014) Frontal white matter integrity in adults with Down syndrome with and without dementia. Neurobiol Aging 35:1562-9|
|Brenowitz, Willa D; Monsell, Sarah E; Schmitt, Frederick A et al. (2014) Hippocampal sclerosis of aging is a key Alzheimer's disease mimic: clinical-pathologic correlations and comparisons with both alzheimer's disease and non-tauopathic frontotemporal lobar degeneration. J Alzheimers Dis 39:691-702|
|Nelson, Peter T; Estus, Steven; Abner, Erin L et al. (2014) ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol 127:825-43|
|Matveev, Sergey V; Spielmann, Hans Peter; Metts, Brittney M et al. (2014) A distinct subfraction of A? is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain. J Neurochem 131:356-68|
|Weekman, Erica M; Sudduth, Tiffany L; Abner, Erin L et al. (2014) Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice. J Neuroinflammation 11:127|
|Parikh, Ishita; Medway, Christopher; Younkin, Steven et al. (2014) An intronic PICALM polymorphism, rs588076, is associated with allelic expression of a PICALM isoform. Mol Neurodegener 9:32|
|Bradley-Whitman, Melissa A; Timmons, Michael D; Beckett, Tina L et al. (2014) Nucleic acid oxidation: an early feature of Alzheimer's disease. J Neurochem 128:294-304|
|Kryscio, Richard J; Abner, Erin L; Cooper, Gregory E et al. (2014) Self-reported memory complaints: implications from a longitudinal cohort with autopsies. Neurology 83:1359-65|
Showing the most recent 10 out of 143 publications